Journal
DIGESTIVE DISEASES
Volume 33, Issue -, Pages 105-112Publisher
KARGER
DOI: 10.1159/000437104
Keywords
Inflammatory bowel disease; Microbiota; Antibiotics; Probiotics; Fecal transplantation; Prebiotics
Categories
Funding
- Abbvie
- Biocodex
- Danone
- Hospira
- Merck medication familiale
- MSD
- Nestle
Ask authors/readers for more resources
Microorganisms present in the intestine possess proinflammatory or anti-inflammatory activities which may modulate inflammatory bowel disease (IBD). The concepts followed by researchers in trying to target the microbiota in IBD were to decrease pathogens or pathobionts, or only the microbial load, and more recently, to favor growth and persistence of favorable microorganisms. We review, here, those concepts and critically analyze the clinical data (especially randomized controlled trials) obtained using antibiotics and probiotics. We eventually present and criticize the rational and data obtained so far following new research strategies including the use of new probiotics, genetically modified organisms and fecal transplantation. (C) 2015 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available